Parameter
| Biomarker | Fibrinogen-like protein 2 (FGL2) | Full name | Fibrinogen-like protein 2 | Molecular Type | Proteins |
|---|---|---|---|---|---|
| Molecular Formula | Human FGL2: C₅₈₈H₉₂₇N₁₅₉O₁₈₀S₆ | Molecular Weight | ~132 kDa | Core Functional Dimensions | Coagulation regulation, immunosuppression, disease progression |
| Disease | Viral Hepatitis | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Serum and tissue samples | ||
| Pathobiological Mechanisms | The membrane type (mFGL2) has prothrombin activity and promotes thrombosis. Soluble (sFGL2) inhibits immune cell function and aggravates liver fibrosis and tumor progression | ||||
| Clinical Availability Status | Clinical research phase | ||||
| Notes and Dynamics | It is involved in the pathological process of a variety of liver diseases, and is a potential therapeutic target and marker for viral hepatitis, liver cancer and other diseases. However, its versatility increases the complexity of clinical application, and targeted intervention strategies need to be developed | ||||